Evaluating and Integrating New Data Into NSCLC Clinical Pathways

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.

Edward Arrowsmith, MD: Something that we at OneOncology consider the core of our mission is being dynamic and improving our therapies. All of us who treat patients with cancer, or really anyone who's had cancer or a loved one with cancer, know that our therapies are not what they need to be. They're not what we want them to be. We're actively trying to improve therapy, both through participation in clinical trials but also by updating our pathways as quickly as we can. There are several ways that we do that. One is that we don't have a cadence for decision-making. We try to make decisions in real time as new data comes out or as new molecular compounds receive FDA approval and are available for use. Another thing we try to do is harvest analysis from all types of different sources to identify patients who may be best for specific therapies. We have active partnerships to have next generation sequencing data available to us as raw computer data that we can then search and find all patients with specific molecular abnormalities and if new treatments become available for those patients. KRAS G12C last summer is a good example of identifying all those patients who maybe had genomic sequencing done a year or 2 ago to make sure we don't overlook any patients who may be good candidates for a specific therapy. The other things that we do are to both have a dedicated clinical team looking for upcoming new therapies but also pool the wisdom across our practices, so if one physician or a handful of physicians are at a conference in Europe, the learnings from that are passed down to all the physicians across OneOncology.

It's been an incredible last 5–10 years in improving the outlook of patients with non-small cell lung cancer, with targeted therapies and immunotherapies becoming available for our patients. Based on the exciting compounds in development, there will be continued improvements in outcome over the next 5–10 years. That's why we at OneOncology are really committed to a dynamic pathways process of continuously updating our pathways and using data to identify the best patients for the best treatments at the best times. It's an exciting time in the care of patients with non-small cell lung cancer, and we are looking forward to the future.

Transcript edited for clarity.